Abstract
Cefpirome, a fourth generation cephalosporin, was administered during 154 episodes of febrile neutropenia in 106 patients. We assessed the clinical efficacy of cefpirome and its activity against isolated pathogens in neutropenic patients with hematologic malignancies. In addition, the pharmacokinetics and optimal dosing regimen of cefpirome during neutropenia were investigated.
| Original language | English |
|---|---|
| Pages (from-to) | 1005-6 |
| Number of pages | 2 |
| Journal | Haematologica |
| Volume | 90 |
| Issue number | 7 |
| Publication status | Published - Jul 2005 |
| Externally published | Yes |
Keywords
- Aged
- Anti-Bacterial Agents/therapeutic use
- Cephalosporins/therapeutic use
- Female
- Fever/drug therapy
- Hematologic Neoplasms/drug therapy
- Humans
- Male
- Middle Aged
- Neutropenia/drug therapy
Fingerprint
Dive into the research topics of 'Cefpirome as empirical treatment for febrile neutropenia in patients with hematologic malignancies'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver